Corcept Therapeutics Reports ALS Survival Breakthrough
REDWOOD CITY, California, April 30, 2026 Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2...
ALS
Advertisement
Pixee Medical Knee+ NexSight Wins FDA 510(k) Clearance
BESANÇON, France, April 28, 2026 Pixee Medical has announced that its next-generation augmented reality (AR) surgical navigation system, Knee+...
Taiho Zipalertinib NDA Accepted by FDA for NSCLC
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
VectorY Therapeutics Secures EMA and MHRA Approval for VTx-002 Trial
AMSTERDAM, Netherlands & BOSTON, Massachusetts, USA, April 28, 2026 VectorY Therapeutics has announced that it has received authorization from...
ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
Advertisements
Trethera Expands ALS Trial with MGH for TRE-515
LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...
XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
ANQUR Trial Shows STMN2 Restoration in ALS Patients
CAMBRIDGE, Mass., Feb. 23, 2026 — QurAlis announced interim clinical results from its Phase 1/2 ANQUR study demonstrating that...
FDA Clears First-in-Class Vectorized Antibody ALS Trial With VTx-002
Amsterdam, The Netherlands, and Boston, MA — January 8, 2026 — VectorY Therapeutics announced that the U.S. Food and...
QurAlis Shows ALS Target Engagement in Phase 1 Trial
CAMBRIDGE, Massachusetts — QurAlis Corporation has announced topline Phase 1 proof-of-mechanism clinical data demonstrating clear target engagement in patients...
Advertisement
